Abstract
Treatments for lung cancer have historically been considered “one-size-fits-all” The development of Precision Oncology, however, has led to increased recognition of non-small cell lung cancer (NSCLC) as a molecularly complex amalgam of diseases with differing outcomes. The 2023 Precision Oncology Summit was held in San Francisco on October 7th and 8th, focused on actionable strategies addressing personalized treatment to improve outcomes of patient with lung cancer. This manuscript summarizes the discussion and key learning points from the precision medicine clinical science symposium in NSCLC, including the latest translational science, and clinical applications updates.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.